Erythromycin significantly alters metabolism of this nonsedating antihistamine; rare serious cardiovascular adverse events including QT/QTc prolongation reported.
Source: NLP:erythromycin lactobionate
6 interactions on record
Erythromycin significantly alters metabolism of this nonsedating antihistamine; rare serious cardiovascular adverse events including QT/QTc prolongation reported.
Source: NLP:erythromycin lactobionate
CYP3A4 inhibitor that increases carbamazepine plasma levels; close monitoring and dosage adjustment may be required.
Source: NLP:carbamazepine
Lanreotide may decrease metabolic clearance of terfenadine; avoid concomitant use or consider dose reduction.
Source: NLP:lanreotide acetate
Octreotide may decrease metabolic clearance of terfenadine through CYP3A4 suppression; use with caution due to low therapeutic index.
Source: NLP:octreotide acetate
No dose adjustment needed when co-administered with montelukast sodium.
Source: NLP:montelukast
No dose adjustment needed when co-administered with montelukast sodium.
Source: NLP:montelukast sodium